Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29928 | 0.91 | MAPT (0.50) | TP53MAPTKDM4EALDH1A1LMNA | |
| Water SCHEMBL11712599 | 0.90 | MAPT (0.48) | TP53MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL11870432 | 0.90 | TP53 (0.48) | TP53MAPTKDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11483295 | 0.90 | MAPT (0.48) | TP53MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL11713103 | 0.90 | MAPT (0.48) | TP53MAPTKDM4EALDH1A1LMNA | |
| Water SCHEMBL11712349 | 0.88 | TP53 (0.47) | TP53MAPTKDM4EALDH1A1LMNA | |
| Water SCHEMBL11717659 | 0.88 | MAPT (0.47) | TP53MAPTKDM4EALDH1A1LMNA | |
| Water SCHEMBL11714649 | 0.88 | MAPT (0.47) | TP53MAPTKDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11711143 | 0.88 | MAPT (0.47) | TP53MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL1078294 | 0.82 | CA5A (0.38) | TP53MAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | disclosed |
| US-20120046281-A1 | RIFALAZIL COMPOSITIONS AND THERAPEUTIC REGIMENS | ACTIVBIOTICS PHARMA, LLC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110217244-A1 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046281-A1 | RIFALAZIL COMPOSITIONS AND THERAPEUTIC REGIMENS | RIF1, CYP3A5, REN | EGFR 4259/4885TP53 4282/4885MAPT 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.